IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.955
NA - Nord America 1.996
EU - Europa 794
SA - Sud America 198
Continente sconosciuto - Info sul continente non disponibili 110
AF - Africa 32
OC - Oceania 13
Totale 8.098
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.605
US - Stati Uniti d'America 1.882
CN - Cina 682
HK - Hong Kong 371
IT - Italia 314
BR - Brasile 121
GB - Regno Unito 115
FR - Francia 93
DE - Germania 91
VN - Vietnam 64
BD - Bangladesh 55
CZ - Repubblica Ceca 54
CA - Canada 47
IN - India 44
MX - Messico 43
FI - Finlandia 26
NL - Olanda 22
CO - Colombia 20
AR - Argentina 19
ID - Indonesia 18
PH - Filippine 14
ZA - Sudafrica 13
AU - Australia 12
EC - Ecuador 12
PL - Polonia 11
ES - Italia 10
MY - Malesia 10
SA - Arabia Saudita 10
UA - Ucraina 10
JP - Giappone 9
PK - Pakistan 9
TR - Turchia 9
PY - Paraguay 8
CL - Cile 7
RU - Federazione Russa 7
TW - Taiwan 7
VE - Venezuela 7
BE - Belgio 6
IQ - Iraq 6
JO - Giordania 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
JM - Giamaica 5
MD - Moldavia 5
NP - Nepal 5
PT - Portogallo 5
GT - Guatemala 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
EE - Estonia 3
GE - Georgia 3
IE - Irlanda 3
KR - Corea 3
LT - Lituania 3
SE - Svezia 3
TN - Tunisia 3
AO - Angola 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
EG - Egitto 2
IL - Israele 2
MA - Marocco 2
MM - Myanmar 2
NI - Nicaragua 2
PE - Perù 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.988
Salva come PNG Salva come JPEG
Città #
San Jose 561
Singapore 409
Hong Kong 369
Ashburn 313
Rome 230
Beijing 210
Hefei 184
Council Bluffs 131
Boardman 106
Columbus 100
London 83
Lauterbourg 79
Dallas 68
Santa Clara 62
Shanghai 61
Munich 48
Los Angeles 39
Brno 35
Mexico City 26
San Francisco 26
New York 25
Ho Chi Minh City 22
Pune 20
Redmond 20
Amsterdam 18
Olomouc 17
São Paulo 16
Hanoi 15
Turku 14
Seattle 13
Washington 13
Guangzhou 12
Helsinki 11
Phoenix 11
Toronto 11
Manchester 10
Boston 9
Bogotá 8
Brooklyn 8
Chicago 8
Montreal 8
Nuremberg 8
Orem 8
Tokyo 8
Warsaw 8
Rio de Janeiro 7
Buffalo 6
Melbourne 6
Milan 6
Amman 5
Campinas 5
Chennai 5
Frankfurt am Main 5
Haiphong 5
Hangzhou 5
Johannesburg 5
Kuala Lumpur 5
Las Vegas 5
Palermo 5
Riyadh 5
San José 5
Ankara 4
Atlanta 4
Biên Hòa 4
Caracas 4
Dhaka 4
Guayaquil 4
Haikou 4
Paris 4
Piscataway 4
Taipei 4
Tashkent 4
Wuhan 4
Alessandria 3
Brasília 3
Buenos Aires 3
Canberra 3
Colombo 3
Columbia 3
Dublin 3
Genoa 3
Guatemala City 3
Hanover 3
Hyderabad 3
Jakarta 3
Karachi 3
Lancaster 3
Manila 3
Mol 3
New Delhi 3
Oklahoma City 3
Philadelphia 3
Quito 3
Québec 3
Stockholm 3
Sydney 3
Tbilisi 3
The Dalles 3
Tirana 3
Xiamen 3
Totale 3.675
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 237
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 231
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 210
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 210
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 209
Cancer drugs and QT prolongation: weighing risk against benefit 208
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 208
Minimal sampling colistin pharmacokinetics in critically ill patients 204
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 199
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 199
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 197
Cardio-oncology in clinical studies and real life 188
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 185
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 181
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 163
Anthracycline Cardiotoxicity 145
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 140
Anthracyclines 131
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 130
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 127
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 126
Anthracycline Cardiotoxicity 116
An introduction to the metabolic determinants of anthracycline cardiotoxicity 108
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 108
Cardiotoxicity of antitumor drugs 104
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 102
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 98
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 95
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 92
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 92
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 80
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 75
Isavuconazole: case report and pharmacokinetic considerations 74
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 72
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 71
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 70
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 70
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 69
Pharmacology of Cardio-Oncology 68
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 66
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 64
What is cardiotoxicity? 64
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 64
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 63
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 63
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 63
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 62
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 62
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 61
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 61
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 59
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 59
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 59
Pharmacological Foundation of Cardio-Oncology 57
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 57
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 55
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 55
The concomitant management of cancer therapy and cardiac therapy 53
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 53
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 48
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 47
Doxorubicin degradation in cardiomyocytes 46
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 46
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 46
Matters of the heart: The case of TNF-alpha targeting drugs 46
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 46
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 46
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 45
Molecular determinants of the reduced cardiotoxicity of epirubicin 45
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 45
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 44
The reality of pixantrone in real life 44
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 44
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 44
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 44
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 42
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 42
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 42
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 42
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 41
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 41
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 41
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 40
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 40
Translating molecular mechanisms into clinical facts 40
In ®Entresto we trust 39
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 38
Humans and Rodents: The Case of hOAT4 and mOat5 37
Do you know pixantrone? 37
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 37
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 36
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 36
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 33
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 32
Indications for the harmonization of the therapeutic ranges for antifungal agents 9
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 9
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 8
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 8
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies 7
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 8.098
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022214 0 0 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20262.976 336 204 131 250 139 94 923 205 219 257 106 112
2026/2027472 74 334 64 0 0 0 0 0 0 0 0 0
Totale 8.098